Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Human Cell Line Produces High-Quality RSV for Vaccine Production

By BiotechDaily International staff writers
Posted on 23 Mar 2014
Image: Electron micrograph reveals the morphologic traits of the respiratory syncytial virus (RSV). The virion is variable in shape, and size (average diameter of between 120–300 nm). RSV is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Image: Electron micrograph reveals the morphologic traits of the respiratory syncytial virus (RSV). The virion is variable in shape, and size (average diameter of between 120–300 nm). RSV is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Cooperation between German and American biotechnology companies may pave the way for development of a vaccine to prevent RSV (respiratory syncytial virus) respiratory infections, which have been estimated to cause nearly 7% of the deaths of infants that die during their first year of life.

The companies involved are CEVEC Pharmaceuticals (Cologne, Germany), a clinical stage pharmaceutical company focusing on the development of highly potent protein and vaccine expression systems based on human CAP cells and Paragon Bioservices Inc. (Baltimore, MD, USA), a leading American biopharmaceutical contract manufacturer.

CEVEC has developed a new and proprietary expression system for biopharmaceuticals offering significant advantages over existing production technologies. Their CAP cells are an immortalized cell line derived from primary human amniocytes that meet the highest ethical and regulatory standards. CEVEC´s CAP cells have proven highly efficient in the production of a broad range of otherwise difficult to express glycoproteins. These molecules are produced at high titers with authentic post-translational modifications in serum-free suspension culture. Their ability to generate human glycosylation patterns also makes CAP cells a valuable tool for vaccine production.

The CEVEC/Paragon project has succeeded in producing RSV in CAP cells that show a high-level of functional G-protein resulting in a very effective RSV vaccine with positive impact on attenuated-vaccine studies.

"Again CAP cells prove their enormous potential and significant advantages over many currently used production systems for vaccines," said Dr. Rainer Lichtenberger, COO of CEVEC. "Next to Cytomegalovirus, influenza, and others, this is another striking example that CAP cells can efficiently propagate disease relevant human viruses. We were very pleased to work with Paragon on this project and benefited from their experience in vaccine production. This collaboration was extremely pleasant and successful."

Marco Chacón, CEO of Paragon said, "This teamwork pays not only for CEVEC, but also for Paragon. With use of CAP cells we can offer our customers a unique production system to meet the challenges of their vaccine target. With this highly ambitious project we have again proven our expertise in this competitive business."

Related Links:

CEVEC Pharmaceuticals
Paragon Bioservices Inc.



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This micrograph depicts the presence of aerobic Gram-negative Neisseria meningitidis diplococcal bacteria; magnification 1150x (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).

Infection by Meningitis Bacteria Depends on Dimerization State of Certain Host Cell Proteins

A team of molecular microbiologists has untangled the complex three-way interaction between the non-integrin laminin receptor (LAMR1), galectin-3 (Gal-2), and the pathogenic bacterium Neisseria meningitidis.... Read more

Lab Technologies

view channel
Image: Yale West Campus is organized into research institutes and core facilities — all designed to promote collaboration and interdisciplinary dialogue (Photo courtesy of Yale University).

American and European Partners Establish a Microscopy Center of Excellence

A prominent American university has announced a partnership agreement with a major European producer of microscopes and imaging tools that will establish a center for the use of cutting-edge imaging technologies... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.